Adisord, 200 mg/5 ml suspension 90 ml

Pharmacodynamics

Nifuroxazide is an antimicrobial agent derived from nitrofuran. It blocks activity of dehydrogenases and inhibits respiratory chains, tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. It destroys microbial cell membrane and decreases production of toxins by microorganisms.

Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.

Weakly sensitive to nifuroxazide: Citrobacter spp., Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp. He disturbs the balance of intestinal microflora.

In acute bacterial diarrhea restores intestinal eubiosis. In case of infection with enterotropic viruses it prevents the development of bacterial superinfection.

Pharmacokinetics

Nifuroxazide is practically not absorbed from the digestive tract after oral administration and its antibacterial effect is exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestine: 20% in unchanged form and the remaining amount of nifuroxazide is chemically changed.

Indications

Acute bacterial diarrhea, occurring without deterioration in general condition, increase in body temperature, or intoxication.

Pharmacological effect

Pharmacodynamics

Nifuroxazide is an antimicrobial agent, a derivative of nitrofuran. Blocks the activity of dehydrogenases and inhibits the respiratory chain, the tricarboxylic acid cycle and a number of other biochemical processes in the microbial cell. Destroys the microbial cell membrane, reduces the production of toxins by microorganisms.

Highly active against Campylobacter jejuni, Escherichia coli, Salmonella spp., Shigella spp.; Clostridium perfringens, Vibrio cholerae, pathogenic Vibrions and Vibrio parahaemolytique, Staphylococcus spp.

Weakly sensitive to nifuroxazide: Citrobacter spp., Enterobacter cloacae and Proteus indologenes. Resistant to nifuroxazide: Klebsiella spp., Proteus mirabilis, Providencia spp., Pseudomonas spp. Does not disturb the balance of intestinal microflora.

In acute bacterial diarrhea, it restores intestinal eubiosis. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.

Pharmacokinetics

After oral administration, nifuroxazide is practically not absorbed from the digestive tract and exerts its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged, and the remaining amount of nifuroxazide is chemically modified.

Special instructions

When treating diarrhea, rehydration therapy must be carried out simultaneously with nifuroxazide therapy. Treatment of diarrhea in children under 3 years of age should be carried out under medical supervision.

In case of bacterial diarrhea with signs of systemic damage (deterioration of general condition, increased body temperature, symptoms of intoxication or infection), you should consult a doctor to decide on the use of systemic antibacterial drugs.

If symptoms of hypersensitivity appear (shortness of breath, rash, itching), you should stop taking the drug. Drinking alcohol during nifuroxazide therapy is prohibited.

Due to the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).

The drug Adisord contains 1000 mg of sucrose per 5 ml. Accordingly, the sucrose content in a single dose of 2.5 ml of suspension is 0.04165 XE (bread units), and in a single dose of 5 ml – 0.0833 XE.

The daily dose of sucrose is 0.0833 XE when taking 2.5 ml of suspension 2 times a day and 0.125 XE when taking 2.5 ml of suspension 3 times a day.

The daily dose of sucrose is 0.250 XE when taking 5 ml of suspension 3 times a day and 0.333 XE when taking 5 ml of suspension 4 times a day.

The content of 96% ethanol in Adisord® suspension is 1%.

The minimum single dose of the drug, corresponding to 100 mg of nifuroxazide (2.5 ml of suspension), contains 0.02 g of ethanol (in terms of absolute alcohol), and the maximum daily dose, corresponding to 800 mg of nifuroxazide (5 ml of suspension 4 times a day), contains 0.16 g of ethanol (in terms of absolute alcohol).

Impact on the ability to drive vehicles and machinery

The drug does not affect the ability to drive vehicles and machinery.

Active ingredient

Nifuroxazide

Composition

5 ml of suspension contains:

Active ingredient:

nifuroxazide 200 mg;

Excipients:

banana flavor (banana essence) 0.6 mg, carbomer 97IP 9 mg, anhydrous citric acid 0.75 mg, methyl parahydroxybenzoate 5 mg, sodium hydroxide 2 mg, sucrose 1000 mg, ethanol 96% 0.05 ml, purified water up to 5 ml.

1 bottle contains:

Active ingredient:

nifuroxazide 3.6 g;

Excipients:

banana flavor (banana essence) 0.0108 g, carbomer 971P 0.162 g, anhydrous citric acid 0.0135 g, methyl parahydroxybenzoate 0.09 g, sodium hydroxide 0.036 g, sucrose 18 g, ethanol 96% 0.9 ml, purified water up to 90 ml.

Pregnancy

In animal studies, no teratogenic effect was detected.

However, as a precaution, taking ifuroxazide during pregnancy is not recommended. During the lactation period, it is possible to continue breastfeeding in case of a short course of treatment with the drug. You should consult your doctor.

Contraindications

Hypersensitivity to nifuroxazide, nitrofuran derivatives and other components of the drug;
Fructose intolerance;
Glucose-galactose malabsorption syndrome, sucrase and isomaltase deficiency;
Pregnancy;
Neonatal period (up to 1 month), prematurity.

With caution

Liver diseases, alcoholism, traumatic brain injury, brain diseases, lactation period, childhood.

Side Effects

Allergic reactions (skin rash, urticaria, Quincke’s edema, anaphylactic shock).

If any of the side effects indicated in the instructions get worse, or you notice any other side effects not listed in the instructions, tell your doctor.

Interaction

Concomitant use with drugs that cause the development of disulfiram-like reactions or drugs that inhibit the function of the central nervous system is not recommended.

If you are taking other medications (including over-the-counter medications), consult your doctor before using Adisord.

Manufacturer

Kanonpharma production CJSC, Russia